- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapies for Pancreatic Cancer
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 2, Pages 36
Publisher
MDPI AG
Online
2018-01-30
DOI
10.3390/cancers10020036
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
- (2018) Sunil R. Hingorani et al. JOURNAL OF CLINICAL ONCOLOGY
- Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).
- (2017) Herbert Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Challenges in Ras therapeutics in pancreatic cancer
- (2017) Minsig Choi et al. SEMINARS IN CANCER BIOLOGY
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis
- (2016) Neng-Yu Lin et al. ANNALS OF THE RHEUMATIC DISEASES
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3
- (2015) Alexey A. Lugovskoy et al. CANCER RESEARCH
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
- (2015) L. A. Chantrill et al. CLINICAL CANCER RESEARCH
- Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
- (2015) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Suppression of cancer relapse and metastasis by inhibiting cancer stemness
- (2015) Youzhi Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway
- (2015) Nikhil Tyagi et al. Oncotarget
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- The MEK/ERK Pathway Promotes NOTCH Signalling in Pancreatic Cancer Cells
- (2014) Isabelle Tremblay et al. PLoS One
- Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
- (2013) Michele Reni et al. EUROPEAN JOURNAL OF CANCER
- The role of insulin and IGF system in pancreatic cancer
- (2013) Marija Trajkovic-Arsic et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Notch inhibitors for cancer treatment
- (2013) Ingrid Espinoza et al. PHARMACOLOGY & THERAPEUTICS
- Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer
- (2012) S.-M. Hong et al. CLINICAL CANCER RESEARCH
- Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
- (2012) Daniel Laheru et al. INVESTIGATIONAL NEW DRUGS
- Epithelial Mesenchymal Transition and Pancreatic Tumor Initiating CD44+/EpCAM+ Cells Are Inhibited by γ-Secretase Inhibitor IX
- (2012) Vindhya Palagani et al. PLoS One
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Many Faces of Wnt and Pancreatic Ductal Adenocarcinoma Oncogenesis
- (2011) Colin D. Weekes et al. Cancers
- Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner
- (2010) Neta Erez et al. CANCER CELL
- Salirasib in the treatment of pancreatic cancer
- (2010) Ernesto Bustinza-Linares et al. Future Oncology
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways
- (2010) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer
- (2009) M. E. Mullendore et al. CLINICAL CANCER RESEARCH
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- Cancer stem cell markers in common cancers – therapeutic implications
- (2008) Thomas Klonisch et al. TRENDS IN MOLECULAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now